Taj Accura offer Full Range of Treatments for Testicular Cancer
Testicular cancer is a cancer which accounts for only 1 % of all cancers, however majority of patients with the disease fall within the younger category from 15-49, with it being the most common cancer in 25-49 year old men. This generally goes against the grain that there is an increased probability of cancer with age, among other risk factors or genetic susceptibility. The only defined risk factor identified is in patients who have experienced cryptorchidism, where one or both testicles failed to descend from the scrotum in the first year of life. Testicular cancer however is an exemplar for the success of chemotherapy treatments, with a predicted 98 % survival rate after 10 years of diagnosis.
Like most cancers, testicular cancer comes with varying stages depending on the stage of disease and is treated with a combination of chemotherapy, surgery or radiotherapy. At Taj Accura Pharmaceuticals, we offer all of the chemotherapeutic regimens suggested for testicular cancer treatment by the American Cancer Society to a global market, with a particular specialisation in hospital and non-governmental organisation (NGO) supply. Chemotherapy is generally conducted following surgery to ensure that the cancer has been treated and to prevent spreading to lymph nodes, and if often used where radiotherapy is deemed unstable. Carboplatin is a common regimen for stage I of the disease in relation to germ cell tumours, which is available as an injectable dosage form in 10 mg, 50 mg, 150 mg or 450 mg dosage forms. The BEP chemotherapeutic regimen indicated for stage II following testicle removal consists of Bleomycin (15 units/30 units available), Etoposide (as an oral or injectable dosage form in an array of doses) and Cisplatin (available in multiple dosages and quantities for injection). For stage III where Bleomycin is contraindicated, the VIP regimen (Vincristine, Ifosfamide and Cisplatin) can be used, which is all available at varying dosages to accommodate for the dosage regimen that requires the factoring in of the patient’s body surface area amongst other variables.
A recent New England Journal of Medicine Review Paper has looked at the treatment of testicular cancer in the past, present and future, where advances have meant a predicted 80 % remission in even metastatic patients is achieved today. Understanding has increased to believe that the event which generates germ cell tumours from gonocytes occurs in utero, only for proliferation to occur once puberty has hit and can thus explain the epidemiology of the disease being predominantly occurring in young to middle aged men. Although genetic analysis is required to fully understand what determines survival in the patient, relapse is common. Current treatment for relapsed testicular cancer remains debatable, with one particular clinical trial (TIGER) comparing low and high dose chemotherapeutic regimens predicted to conjure a lot of interest in regards to clinical guidelines. Current splits in the treatment of relapse are between BEP (bleomycin, etoposide, cisplatin) or VIP (vincristine, ifosfamide and cisplatin). A new chemotherapeutic regimen considering the use of paclitaxel, ifosfamide and cisplatin (TIP) has also been considered in recent times, with clinical trials underway to determine its efficacy in comparison to BEP chemotherapy regimens.